HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals

O. Pontesilli, M. Carlesimo, A. R. Varani, R. Ferrara, E. C. Guerra, M. L. Bernardi, G. Ricci, A. M. Mazzone, G. D'Offizi, F. Aiuti

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In vitro lymphoproliferative responses to HIV-1 recombinant antigens (gp160, p24, and Rev protein) were studied in 83 patients with asymptomatic HIV-1 infection (CDC groups II and III) and circulating CD4 lymphocyte numbers > 400/mm3. Significant response to at least one of the three antigens was detected in 52.4% of the subjects, but the responses were weak, and concordance of the response to the three antigens was rare, the frequency of individuals responding to each antigen not exceeding 22.4%. Increasing frequencies of response were observed when recall antigens (tetanus toxoid and Candida albicans glycomannoprotein) (65.5%) and anti-CD3 MoAb (76.6%) were used as stimuli. Although a significant association between lymphocyte response to p24, but not gp160, and steadiness of CD4 lymphocyte numbers before the assay was observed, no predictive value for lack of CD4 cell decrease was confirmed for either antigen, and fluctuation of the responses to HIV antigens was seen during subsequent follow up. The panel of T cell assays used could be regarded as appropriate for monitoring both HIV-specific responses and T lymphocyte function during immunotherapy with soluble HIV antigens.

Original languageEnglish
Pages (from-to)419-424
Number of pages6
JournalClinical and Experimental Immunology
Volume100
Issue number3
Publication statusPublished - 1995

Fingerprint

HIV
Antigens
HIV Antigens
Lymphocyte Count
HIV-1
rev Gene Products
T-Lymphocytes
Tetanus Toxoid
Centers for Disease Control and Prevention (U.S.)
Candida albicans
Immunotherapy
HIV Infections
Lymphocytes

Keywords

  • gp160
  • HIV
  • lymphocyte
  • p24
  • proliferation

ASJC Scopus subject areas

  • Immunology

Cite this

Pontesilli, O., Carlesimo, M., Varani, A. R., Ferrara, R., Guerra, E. C., Bernardi, M. L., ... Aiuti, F. (1995). HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. Clinical and Experimental Immunology, 100(3), 419-424.

HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. / Pontesilli, O.; Carlesimo, M.; Varani, A. R.; Ferrara, R.; Guerra, E. C.; Bernardi, M. L.; Ricci, G.; Mazzone, A. M.; D'Offizi, G.; Aiuti, F.

In: Clinical and Experimental Immunology, Vol. 100, No. 3, 1995, p. 419-424.

Research output: Contribution to journalArticle

Pontesilli, O, Carlesimo, M, Varani, AR, Ferrara, R, Guerra, EC, Bernardi, ML, Ricci, G, Mazzone, AM, D'Offizi, G & Aiuti, F 1995, 'HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals', Clinical and Experimental Immunology, vol. 100, no. 3, pp. 419-424.
Pontesilli O, Carlesimo M, Varani AR, Ferrara R, Guerra EC, Bernardi ML et al. HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. Clinical and Experimental Immunology. 1995;100(3):419-424.
Pontesilli, O. ; Carlesimo, M. ; Varani, A. R. ; Ferrara, R. ; Guerra, E. C. ; Bernardi, M. L. ; Ricci, G. ; Mazzone, A. M. ; D'Offizi, G. ; Aiuti, F. / HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals. In: Clinical and Experimental Immunology. 1995 ; Vol. 100, No. 3. pp. 419-424.
@article{2e90b4b6fe6646b3b3d8f4386b67d05c,
title = "HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals",
abstract = "In vitro lymphoproliferative responses to HIV-1 recombinant antigens (gp160, p24, and Rev protein) were studied in 83 patients with asymptomatic HIV-1 infection (CDC groups II and III) and circulating CD4 lymphocyte numbers > 400/mm3. Significant response to at least one of the three antigens was detected in 52.4{\%} of the subjects, but the responses were weak, and concordance of the response to the three antigens was rare, the frequency of individuals responding to each antigen not exceeding 22.4{\%}. Increasing frequencies of response were observed when recall antigens (tetanus toxoid and Candida albicans glycomannoprotein) (65.5{\%}) and anti-CD3 MoAb (76.6{\%}) were used as stimuli. Although a significant association between lymphocyte response to p24, but not gp160, and steadiness of CD4 lymphocyte numbers before the assay was observed, no predictive value for lack of CD4 cell decrease was confirmed for either antigen, and fluctuation of the responses to HIV antigens was seen during subsequent follow up. The panel of T cell assays used could be regarded as appropriate for monitoring both HIV-specific responses and T lymphocyte function during immunotherapy with soluble HIV antigens.",
keywords = "gp160, HIV, lymphocyte, p24, proliferation",
author = "O. Pontesilli and M. Carlesimo and Varani, {A. R.} and R. Ferrara and Guerra, {E. C.} and Bernardi, {M. L.} and G. Ricci and Mazzone, {A. M.} and G. D'Offizi and F. Aiuti",
year = "1995",
language = "English",
volume = "100",
pages = "419--424",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - HIV-specific lymphoproliferative responses in asymptomatic HIV-infected individuals

AU - Pontesilli, O.

AU - Carlesimo, M.

AU - Varani, A. R.

AU - Ferrara, R.

AU - Guerra, E. C.

AU - Bernardi, M. L.

AU - Ricci, G.

AU - Mazzone, A. M.

AU - D'Offizi, G.

AU - Aiuti, F.

PY - 1995

Y1 - 1995

N2 - In vitro lymphoproliferative responses to HIV-1 recombinant antigens (gp160, p24, and Rev protein) were studied in 83 patients with asymptomatic HIV-1 infection (CDC groups II and III) and circulating CD4 lymphocyte numbers > 400/mm3. Significant response to at least one of the three antigens was detected in 52.4% of the subjects, but the responses were weak, and concordance of the response to the three antigens was rare, the frequency of individuals responding to each antigen not exceeding 22.4%. Increasing frequencies of response were observed when recall antigens (tetanus toxoid and Candida albicans glycomannoprotein) (65.5%) and anti-CD3 MoAb (76.6%) were used as stimuli. Although a significant association between lymphocyte response to p24, but not gp160, and steadiness of CD4 lymphocyte numbers before the assay was observed, no predictive value for lack of CD4 cell decrease was confirmed for either antigen, and fluctuation of the responses to HIV antigens was seen during subsequent follow up. The panel of T cell assays used could be regarded as appropriate for monitoring both HIV-specific responses and T lymphocyte function during immunotherapy with soluble HIV antigens.

AB - In vitro lymphoproliferative responses to HIV-1 recombinant antigens (gp160, p24, and Rev protein) were studied in 83 patients with asymptomatic HIV-1 infection (CDC groups II and III) and circulating CD4 lymphocyte numbers > 400/mm3. Significant response to at least one of the three antigens was detected in 52.4% of the subjects, but the responses were weak, and concordance of the response to the three antigens was rare, the frequency of individuals responding to each antigen not exceeding 22.4%. Increasing frequencies of response were observed when recall antigens (tetanus toxoid and Candida albicans glycomannoprotein) (65.5%) and anti-CD3 MoAb (76.6%) were used as stimuli. Although a significant association between lymphocyte response to p24, but not gp160, and steadiness of CD4 lymphocyte numbers before the assay was observed, no predictive value for lack of CD4 cell decrease was confirmed for either antigen, and fluctuation of the responses to HIV antigens was seen during subsequent follow up. The panel of T cell assays used could be regarded as appropriate for monitoring both HIV-specific responses and T lymphocyte function during immunotherapy with soluble HIV antigens.

KW - gp160

KW - HIV

KW - lymphocyte

KW - p24

KW - proliferation

UR - http://www.scopus.com/inward/record.url?scp=0029053681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029053681&partnerID=8YFLogxK

M3 - Article

VL - 100

SP - 419

EP - 424

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -